Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Tvardi Therapeutics, Inc. (NASDAQ: TVRD), a clinical-stage biopharmaceutical company, has announced its participation in the Piper Sandler 37th Annual Healthcare Conference scheduled for December 2-4, 2025, in New York, NY. Tvardi, which specializes in developing novel, oral small molecule therapies, focuses on targeting the STAT3 protein to address fibrosis-driven diseases—a field marked by significant unmet medical needs.

The company’s management will engage in a fireside chat on December 2, 2025, at 12:00 PM ET and will also host one-on-one investor meetings during the conference. The fireside chat will be accessible via a webcast on Tvardi's investor website, with a replay available for approximately 90 days post-conference.

Tvardi's innovative approach centers around STAT3, a key player in several fibrotic signaling pathways that contribute to issues such as uncontrolled cell proliferation, immune suppression, and the deposition of fibrotic tissue. Furthermore, STAT3's role extends into oncology, as it is also associated with the survival and immune evasion of cancer cells. Currently, Tvardi is conducting clinical trials involving its lead drug candidates, TTI-101 and TTI-109, which are being investigated for their effectiveness in treating hepatocellular carcinoma and are also undergoing trials in healthy volunteers.

Overall, Tvardi is positioned at the forefront of a promising therapeutic area. With its focus on oral small molecules aimed at targeting STAT3, the company is working to create impactful solutions in the treatment of fibrotic diseases and cancer. For more detailed information, potential investors and stakeholders are encouraged to visit Tvardi's website or connect via LinkedIn and Twitter.

Tvardi Therapeutics Inc. (NASDAQ: TVRD) is a clinical-stage biopharmaceutical company poised to make significant waves in the biotech sector, particularly with its unique focus on targeting STAT3 to address fibrosis-driven diseases. As Tvardi prepares to participate in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025, investors should closely monitor this event to gauge the company’s progress and strategic direction.

The highlight of this conference will be Tvardi’s fireside chat on December 2 at 12:00 PM ET. This format typically allows for an in-depth discussion that can reveal critical insights into the company’s pipeline, particularly regarding their lead compounds, TTI-101 and TTI-109. With ongoing clinical trials—TTI-101 for hepatocellular carcinoma (NCT05440708) and TTI-109 in healthy volunteers—investors should look for updates regarding trial progress, timelines, and potential preliminary efficacy results that could significantly influence stock valuation.

Given the high unmet need in treating fibrosis and the broad applicability of targeting STAT3, positive updates can bolster investor confidence and drive stock prices higher. Furthermore, the market for cancer therapies remains robust, and any advancements in Tvardi’s clinical trials could position the company favorably against peers, especially as they enter later-stage trials.

For those considering investments in Tvardi, attending the fireside chat or viewing the webcast replay could provide valuable insights that feed into a well-rounded investment decision. Potential investors should keep an eye on broader industry trends and remain vigilant about risk factors associated with clinical-stage biopharmaceutical stocks, including regulatory hurdles and competition. In summary, with a focused therapeutic pipeline aimed at significant medical needs, Tvardi Therapeutics represents a compelling opportunity for investors in the biopharmaceutical arena.